Highlights

  • Chrysos Corporation has secured a new A$200 million syndicated Debt Facility to replace its existing financing structure.
  • The facility improves financial flexibility, reduces costs, and increases funding capacity by approximately A$105 million.
  • Strong global Demand for PhotonAssay™ technology is driving expansion, with continued growth in Lease agreements and sample processing volumes.

Overview

Chrysos Corporation Ltd (ASX:C79) has executed a new three-year A$200 million syndicated corporate debt facility with three leading domestic financiers, replacing its previous asset-based financing structure. The new arrangement enhances operational flexibility, lowers borrowing costs, and significantly increases available funding headroom. It is designed to support the company’s expansion strategy, including Manufacturing, deployment, and global scaling of its PhotonAssay™ units. Strong commercial momentum, rising adoption across multiple regions, and consistent high utilisation rates have reinforced Chrysos’ growth outlook. The facility positions the company to accelerate production capacity and meet growing international demand through FY27 and beyond.

Why Is Chrysos Shifting to a Corporate Debt Structure Now?

The transition to a corporate-style debt facility reflects Chrysos’ evolution from an early-stage scaling Business into a globally expanding technology provider. The new structure replaces its previous asset-backed financing with a more flexible syndicated arrangement involving ANZ, NAB, and Export Finance Australia. This shift improves pricing, reduces commitment fees, and strengthens covenant terms while increasing funding headroom by A$105 million. The facility also supports Long-term Growth plans, enabling the company to scale production and deployment of PhotonAssay™ units across multiple international jurisdictions while maintaining financial stability and operational agility.

How Will the $200 Million Facility Support Chrysos’ Global Expansion Strategy?

The new funding package provides Chrysos with the Capital required to accelerate manufacturing and deployment of its PhotonAssay™ technology, which is experiencing strong global adoption. The company plans to return to a production cadence of around 18 units annually, supported by a forward order book of 22 units and additional long-lead components. Recent commercial activity, including multiple new lease agreements and expanded partnerships with global laboratory operators, highlights growing demand. With consistent monthly processing volumes exceeding one million samples, the facility ensures Chrysos can scale operations, expand its international footprint, and maintain momentum through FY27 and beyond.